Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Aptevo Therapeutics (Nasdaq:APVO) CEO Marvin White will be featured on Bloomberg TV's RedChip Small Stocks, Big Money™ show on February 15, 2025. The interview will highlight the company's progress in developing bispecific immuno-oncology therapeutics.
The company's lead candidate, Mipletamig (CD3 x CD123), targeting the $6.3B AML market, has shown promising results in clinical trials with over 100 patients. In the RAINIER dose optimization trial, 100% of patients achieved remission within 30 days of treatment.
Their second clinical candidate, ALG.APV-527 (5T4 x 4-1BB), targeting solid tumors, demonstrated stable disease in 59% of patients (10/17) in recent dose escalation trials, with some patients maintaining stability for up to 12 months. The company also has three preclinical candidates in development.
Aptevo Therapeutics (Nasdaq:APVO) il CEO Marvin White sarà ospite del programma RedChip Small Stocks, Big Money™ su Bloomberg TV il 15 febbraio 2025. L'intervista metterà in evidenza i progressi dell'azienda nello sviluppo di terapie immuno-oncologiche bispecifiche.
Il candidato principale dell'azienda, Mipletamig (CD3 x CD123), che si rivolge al mercato dell'AML da 6,3 miliardi di dollari, ha mostrato risultati promettenti negli studi clinici con oltre 100 pazienti. Nello studio di ottimizzazione della dose RAINIER, il 100% dei pazienti ha raggiunto la remissione entro 30 giorni dal trattamento.
Il loro secondo candidato clinico, ALG.APV-527 (5T4 x 4-1BB), che mira ai tumori solidi, ha dimostrato una malattia stabile nel 59% dei pazienti (10/17) negli recenti studi di escalazione della dose, con alcuni pazienti che hanno mantenuto la stabilità per un massimo di 12 mesi. L'azienda ha anche tre candidati preclinici in fase di sviluppo.
Aptevo Therapeutics (Nasdaq:APVO) el CEO Marvin White aparecerá en el programa RedChip Small Stocks, Big Money™ de Bloomberg TV el 15 de febrero de 2025. La entrevista destacará los avances de la compañía en el desarrollo de terapias inmuno-oncológicas bispecíficas.
El candidato principal de la compañía, Mipletamig (CD3 x CD123), que apunta al mercado de AML de 6.3 mil millones de dólares, ha mostrado resultados prometedores en ensayos clínicos con más de 100 pacientes. En el ensayo de optimización de dosis RAINIER, el 100% de los pacientes logró remisión en 30 días de tratamiento.
Su segundo candidato clínico, ALG.APV-527 (5T4 x 4-1BB), dirigido a tumores sólidos, demostró enfermedad estable en el 59% de los pacientes (10/17) en los recientes ensayos de escalada de dosis, con algunos pacientes manteniendo estabilidad durante hasta 12 meses. La compañía también tiene tres candidatos preclínicos en desarrollo.
Aptevo Therapeutics (Nasdaq:APVO)의 CEO Marvin White는 2025년 2월 15일 Bloomberg TV의 RedChip Small Stocks, Big Money™ 프로그램에 출연할 예정입니다. 인터뷰에서는 회사의 이중 특이 면역 종양학 치료제 개발 진행 상황이 강조될 것입니다.
회사의 주요 후보인 Mipletamig (CD3 x CD123)은 63억 달러 규모의 AML 시장을 목표로 하며, 100명 이상의 환자를 대상으로 한 임상 시험에서 유망한 결과를 보였습니다. RAINIER 용량 최적화 시험에서는 100%의 환자가 치료 후 30일 이내에 완전 관해에 도달했습니다.
그들의 두 번째 임상 후보인 ALG.APV-527 (5T4 x 4-1BB)은 고형 종양을 겨냥하고 있으며, 최근 용량 증량 시험에서 환자의 59% (10/17)에서 안정적인 질병을 나타냈고, 일부 환자는 최대 12개월 동안 안정성을 유지했습니다. 회사는 또한 개발 중인 세 가지 전임상 후보가 있습니다.
Aptevo Therapeutics (Nasdaq:APVO) le PDG Marvin White sera présenté dans l'émission RedChip Small Stocks, Big Money™ de Bloomberg TV le 15 février 2025. L'interview mettra en lumière les progrès de l'entreprise dans le développement de thérapies immuno-oncologiques bispécifiques.
Le principal candidat de l'entreprise, Mipletamig (CD3 x CD123), qui cible le marché de l'AML de 6,3 milliards de dollars, a montré des résultats prometteurs lors des essais cliniques avec plus de 100 patients. Dans l'essai d'optimisation de dose RAINIER, 100% des patients ont atteint une rémission dans les 30 jours suivant le traitement.
Leur deuxième candidat clinique, ALG.APV-527 (5T4 x 4-1BB), visant les tumeurs solides, a démontré une maladie stable chez 59% des patients (10/17) lors des récents essais d'escalade de dose, certains patients maintenant une stabilité pendant jusqu'à 12 mois. L'entreprise a également trois candidats précliniques en développement.
Aptevo Therapeutics (Nasdaq:APVO) CEO Marvin White wird am 15. Februar 2025 in der Sendung RedChip Small Stocks, Big Money™ auf Bloomberg TV zu sehen sein. Im Interview wird der Fortschritt des Unternehmens bei der Entwicklung von bispezifischen immunonkologischen Therapeutika hervorgehoben.
Der Hauptkandidat des Unternehmens, Mipletamig (CD3 x CD123), der auf den 6,3 Milliarden Dollar schweren AML-Markt abzielt, hat in klinischen Studien mit über 100 Patienten vielversprechende Ergebnisse gezeigt. In der Dosisoptimierungsstudie RAINIER erreichten 100% der Patienten innerhalb von 30 Tagen nach der Behandlung eine Remission.
Ihr zweiter klinischer Kandidat, ALG.APV-527 (5T4 x 4-1BB), der sich auf solide Tumoren konzentriert, zeigte in den letzten Dosissteigerungsstudien bei 59% der Patienten (10/17) eine stabile Erkrankung, wobei einige Patienten die Stabilität bis zu 12 Monate lang aufrechterhielten. Das Unternehmen hat auch drei präklinische Kandidaten in der Entwicklung.
- 100% remission rate within 30 days in RAINIER trial for lead candidate Mipletamig
- 59% of patients achieved stable disease in ALG.APV-527 trials
- Pipeline targeting large market opportunity (AML market valued at $6.3B)
- Multiple patients maintained stable disease for up to 12 months in ALG.APV-527 trials
- Mipletamig still in early stages of clinical development, pending FDA approval
- Current products are investigational with no approved drugs in portfolio
Marvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth
ORLANDO, FL / ACCESS Newswire / February 15, 2025 / RedChip Companies announced today that an interview with Aptevo Therapeutics' (Nasdaq:APVO) President and CEO Marvin White, will air on RedChip's Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, Saturday, February 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interview in its entirety: https://youtu.be/mOAdCU_o0XE
In an exclusive interview, Marvin White, President and CEO of Aptevo, will appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's recent accomplishments and innovative approach to the development of bispecific immuno-oncology therapeutics that are differentiated by design. Lead candidate, Mipletamig (CD3 x CD123)targets AML (a
The Company's second clinical candidate, ALG.APV-527 (5T4 x 4-1BB), is a first-in-class solid tumor bispecific targeting 5T4-expressing solid tumor cancers. Recent results from a dose escalation trial showed that
APVO is a client of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About Aptevo Therapeutics
Aptevo Therapeutics Inc. (Nasdaq:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a two part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR® and ADAPTIR-FLEX®. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax + azacitidine on a targeted patient population will continue to show remissions, whether Aptevo's final trial results will vary from its earlier assessment, whether Aptevo's strategy will translate into an improved overall survival in AML, especially among patient subgroups with poor prognosis, whether further study of ALG.APV-527 across multiple tumor types will continue to show clinical benefit, the possibility and timing of interim data readouts for ALG.APV-527, statements related to Aptevo's cash position and balance sheet, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine and the war between Israel and Hamas, and macroeconomic conditions such as economic uncertainty, rising inflation and interest rates, continued market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
Miriam Weber Miller
Head, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628
--END--
SOURCE: RedChip
View the original press release on ACCESS Newswire
FAQ
What were the results of Aptevo's (APVO) RAINIER trial for Mipletamig in 2025?
What is the market size for Aptevo's (APVO) AML treatment Mipletamig?
What are the clinical results for Aptevo's (APVO) ALG.APV-527 solid tumor treatment?
How many patients has Aptevo's (APVO) Mipletamig treated in clinical trials?
